Tandem Diabetes Care (TNDM) 2018年年度报告「NASDAQ」.pdf

1、2018 ANNUAL REPORTTransformational Growthwith Basal-IQ Technology400501001502002503003503HRSmg/dL883:24 PMNovember 14100%235 u123INSULIN ON BOARD1.1 u|1:09 hrs003HRS3 3Predicts and helps prevent lows?*with Basal-IQ TechnologyBasal-IQ technology is not a substitute for active self-management of your

2、diabetes.Visit for more information.*If glucose alerts and CGM readings do not match symptoms or expectations,use a blood glucose meter to make diabetes treatment decisions.1.Forlenza GP,Li Z,Buckingham BA,Pinsker JE,et al.Predictive low-glucose suspend reduces hypoglycemia in adults,adolescents,and

3、 children with type 1 diabetes in an at-home randomized crossover study:Results of the PROLOG trial.Diabetes Care.2018;41(10):2155-2161.doi:10.2337/dc18-0771.Visit to learn more.?*?Simple to use?1Less time low?131%91%CLINICAL STUDY RESULTS:DEAR FELLOW STOCKHOLDERS,Independently,each of these had the

4、 po-tential to drive growth during the year.What resulted was our successful execution across each of these opportunities,which drove 71%year-over-year sales growth and our achievement of more than 100%growth in shipments for the year.We are equally proud that we made steady improvement in both oper

5、ating and gross margins throughout 2018.This resulted in our substantial reduction of cash use which,combined with our elimination of debt,allowed us to reach the milestone of generating cash in the fourth quartera full year ahead of our expectations.These accomplishments further reinforce our confi

6、dence in attaining our long-term profitability goals.Our remarkable achievements in 2018 can be credited to the hard work and dedication of our employees.Together,we persevered in support of our mission through challeng-ing times and as a result have now touched the lives of nearly 85,000 people who